Shots: The approval is based on two studies i.e. FIREFISH and SUNFISH. The FIREFISH study involves assessing Evrysdi in infants aged 2-7mos. with symptomatic Type 1 SMA, and the SUNFISH […]readmore
Tags : (risdiplam)
Shots: Roche reports the new 2-year data from Part 1 of the FIREFISH study assessing Evrysdi in infants aged 2-7mos. with symptomatic Type 1 SMA. The 2-year results in infants […]readmore